Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

about

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

Item

http://www.wikidata.org/entity/Q40042219

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Access criteria for anti-TNF a ...... cost-effectiveness estimates.

@en

type

Item

label

Access criteria for anti-TNF a ...... cost-effectiveness estimates.

@en

prefLabel

Access criteria for anti-TNF a ...... cost-effectiveness estimates.

@en

P1476

Access criteria for anti-TNF a ...... cost-effectiveness estimates.

@en

P2093

Aslam Anis

http://www.w3.org/2001/XMLSchema#string

Daphne Guh

http://www.w3.org/2001/XMLSchema#string

Nick Bansback

http://www.w3.org/2001/XMLSchema#string

Stephanie Harvard

http://www.w3.org/2001/XMLSchema#string

P2860

TNF-alpha inhibitors for ankylosing spondylitis

What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines.

Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register.

Health outcomes in economic evaluation: the QALY and utilities.

Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.

Epidemiology of spondyloarthritis in North America

Predicting the outcome of ankylosing spondylitis therapy

Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial

P2888

s12962-017-0081-8

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12962-017-0081-8

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pascal Richette

Bruno Fautrel

Alain Saraux

P577

2017-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091502594

http://www.w3.org/2001/XMLSchema#string

P698

28904528

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor

P932

5590198

http://www.w3.org/2001/XMLSchema#string